Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen N Davis

Showing results (21-30 of 127) with videos related to

Pageof 13
Sort By:
Expert Opinion on Drug Metabolism & Toxicology|March 22, 2012
Evaluation of colesevelam hydrochloride for the treatment of type 2 diabetesLisa M Younk, Stephen N Davis
Expert Opinion on Pharmacotherapy|August 3, 2023
How close are we to personalized pharmacotherapies and innovative technology for type 1 diabetes management?Kashif M Munir, Stephen N Davis
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 16, 2008
Role of the endocannabinoid system in management of patients with type 2 diabetes mellitus and cardiovascular risk factorsStephen N Davis, Jennifer M Perkins
Expert Opinion on Investigational Drugs|December 21, 2016
Discontinued drug therapies to treat diabetes in 2015Maka S Hedrington, Stephen N Davis
The Diabetes Educator|July 13, 2006
Treating to target in type 2 diabetes: a case presentationStephen N Davis, Susan M Renda
Expert Opinion on Drug Metabolism & Toxicology|May 31, 2018
Peroxisome proliferator-activated receptor alpha-mediated drug toxicity in the liverMaka S Hedrington, Stephen N Davis
Clinical Pharmacology : Advances and Applications|May 18, 2016
Differential pharmacology and clinical utility of empagliflozin in type 2 diabetesKashif M Munir, Stephen N Davis
Expert Opinion on Pharmacotherapy|May 24, 2018
Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes?Kashif M Munir, Stephen N Davis
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|April 12, 2026
Hot flashes, cold feet: a cautious embrace of regulatory reformRaya Elfadel Kheirbek, Stephen N Davis
Journal of Diabetes and Its Complications|March 5, 2003
Leptin: metabolic control and regulationDarleen A Sandoval, Stephen N Davis
Pageof 13

Showing results (21-30 of 127) with videos related to

Sort By:
Pageof 13
Expert Opinion on Drug Metabolism & Toxicology|March 22, 2012
Evaluation of colesevelam hydrochloride for the treatment of type 2 diabetesLisa M Younk, Stephen N Davis
Expert Opinion on Pharmacotherapy|August 3, 2023
How close are we to personalized pharmacotherapies and innovative technology for type 1 diabetes management?Kashif M Munir, Stephen N Davis
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 16, 2008
Role of the endocannabinoid system in management of patients with type 2 diabetes mellitus and cardiovascular risk factorsStephen N Davis, Jennifer M Perkins
Expert Opinion on Investigational Drugs|December 21, 2016
Discontinued drug therapies to treat diabetes in 2015Maka S Hedrington, Stephen N Davis
The Diabetes Educator|July 13, 2006
Treating to target in type 2 diabetes: a case presentationStephen N Davis, Susan M Renda
Expert Opinion on Drug Metabolism & Toxicology|May 31, 2018
Peroxisome proliferator-activated receptor alpha-mediated drug toxicity in the liverMaka S Hedrington, Stephen N Davis
Clinical Pharmacology : Advances and Applications|May 18, 2016
Differential pharmacology and clinical utility of empagliflozin in type 2 diabetesKashif M Munir, Stephen N Davis
Expert Opinion on Pharmacotherapy|May 24, 2018
Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes?Kashif M Munir, Stephen N Davis
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|April 12, 2026
Hot flashes, cold feet: a cautious embrace of regulatory reformRaya Elfadel Kheirbek, Stephen N Davis
Journal of Diabetes and Its Complications|March 5, 2003
Leptin: metabolic control and regulationDarleen A Sandoval, Stephen N Davis
Pageof 13